Sponsor Pipeline

ALX Oncology Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
2
Recruiting
1
Phase 3
6
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-15 NCT07007559
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in…
Trial sites expanded: 44 -> 54 locations
Active Trials by Phase
Phase 2/3
1
Phase 2
3
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2/3
NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) Gastric Cancer Active, Not Recruiting
Phase 2
NCT07007559 ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in… Breast Cancer, Metastatic Recruiting
NCT04675294 Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and… Head and Neck Cancer Active, Not Recruiting
NCT04675333 Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With… Head and Neck Cancer Active, Not Recruiting
Phase 1
NCT07085091 A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors NSCLC (Advanced Non-small Cell Lung Cancer) Recruiting
Disease Areas
Get alerts when ALX Oncology Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free